<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1684-1824</journal-id>
<journal-title><![CDATA[Revista Médica Electrónica]]></journal-title>
<abbrev-journal-title><![CDATA[Rev.Med.Electrón.]]></abbrev-journal-title>
<issn>1684-1824</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Ciencias Médicas de Matanzas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1684-18242023000500845</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Marcadores lipídicos en los pacientes con VIH/sida en tratamiento con inhibidores de la proteasa]]></article-title>
<article-title xml:lang="en"><![CDATA[Lipid markers in HIV AIDS patients under treatment with protease inhibitors]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Linares-Morera]]></surname>
<given-names><![CDATA[Anmy]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vidal-Casal]]></surname>
<given-names><![CDATA[Joan Javier]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martínez-Fadraga]]></surname>
<given-names><![CDATA[Yuleimy]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Medina-Rodríguez]]></surname>
<given-names><![CDATA[Liena]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Santos-Matos]]></surname>
<given-names><![CDATA[Leydis]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vidal-Linares]]></surname>
<given-names><![CDATA[Joan Ariel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Universitario Clínico Quirúrgico Comandante Faustino Pérez  ]]></institution>
<addr-line><![CDATA[ Matanzas]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Provincial Ginecobstétrico Docente José Ramón López Tabrane  ]]></institution>
<addr-line><![CDATA[ Matanzas]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad de Ciencias Médicas de Matanzas  ]]></institution>
<addr-line><![CDATA[ Matanzas]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>10</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>10</month>
<year>2023</year>
</pub-date>
<volume>45</volume>
<numero>5</numero>
<fpage>845</fpage>
<lpage>858</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1684-18242023000500845&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1684-18242023000500845&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1684-18242023000500845&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  Las enfermedades cardiovasculares constituyen la principal causa de morbimortalidad a escala mundial. Otra enfermedad con impacto significativo en los sistemas de salud pública es el VIH/sida. Los pacientes infectados con el virus de la inmunodeficiencia humana, tienen mayor riesgo de desarrollar enfermedades cardiovasculares. Posterior al tratamiento antirretroviral ha disminuido la incidencia de enfermedades oportunistas asociadas al VIH/sida, y se ha elevado la incidencia de enfermedades asociadas al envejecimiento, como la enfermedad cardiovascular. El uso de antirretrovirales inhibidores de la proteasa se asocia a hiperlipidemia y, por consiguiente, al aumento de complicaciones cardiovasculares.  Objetivo:  Determinar los marcadores lipídicos en pacientes con VIH/sida en tratamiento con inhibidores de la proteasa.  Materiales y métodos:  Se realizó un estudio observacional, analítico, transversal en los pacientes con VIH/sida de la provincia de Matanzas, durante el período comprendido entre marzo y agosto de 2020, en el Laboratorio Clínico del Hospital Universitario Clínico Quirúrgico Comandante Faustino Pérez Hernández.  Resultados:  Se evaluaron los marcadores lipídicos como factor de riesgo cardiovascular asociado al tratamiento antirretroviral, siendo los triglicéridos el de mayor incidencia.  Conclusiones:  Se identificaron los marcadores lipídicos como factores de riesgo cardiovascular, en este caso la hipertrigliceridemia.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  Cardiovascular diseases are the main risk of morbidity and mortality worldwide. Another disease with significant impact on public health systems is HIV/AIDS. Patients infected with the human immunodeficiency virus have a higher risk of developing cardiovascular diseases. After antiretroviral treatment, the incidence of opportunistic diseases associated with HIV/AIDS has decreased and the incidence of diseases associated with aging such as cardiovascular disease has increased. The use of protease inhibitor antiretroviral drugs is associated with hyperlipidemia and a consequent increase in cardiovascular complications.  Objective:  To determine lipid markers in patients with HIV/AIDS undergoing treatment with protease inhibitors.  Materials and method:  An observational, analytical, cross-sectional study was carried out in patients with HIV/AIDS from the province of Matanzas during the period from March to August 2020, in the Clinical Laboratory of the Provincial Teaching Clinical Surgical Hospital Faustino Pérez Hernandez.  Results:  Lipid markers were evaluated as cardiovascular risk factor associated with antiretroviral treatment, with triglycerides being the one of highest incidence.  Conclusions:  Lipid markers were identified as cardiovascular risk factors; in this case hypertriglyceridemia.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[enfermedad cardiovascular]]></kwd>
<kwd lng="es"><![CDATA[VIH]]></kwd>
<kwd lng="es"><![CDATA[sida]]></kwd>
<kwd lng="es"><![CDATA[antirretrovirales]]></kwd>
<kwd lng="es"><![CDATA[factores de riesgo cardiovascular]]></kwd>
<kwd lng="en"><![CDATA[cardiovascular disease]]></kwd>
<kwd lng="en"><![CDATA[HIV]]></kwd>
<kwd lng="en"><![CDATA[AIDS]]></kwd>
<kwd lng="en"><![CDATA[antiretroviral drugs]]></kwd>
<kwd lng="en"><![CDATA[cardiovascular risk factors]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<collab>ONUSIDA</collab>
<source><![CDATA[Monitoreo Global del SIDA 2020]]></source>
<year>2019</year>
<publisher-loc><![CDATA[Ginebra ]]></publisher-loc>
<publisher-name><![CDATA[ONUSIDA]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<collab>Grupo de expertos del Grupo de Estudio sobre Alteraciones Metabólicas, de la Secretaría del Plan Nacional sobre el Sida y del Grupo de Estudio de Sida</collab>
<article-title xml:lang=""><![CDATA[Documento de consenso sobre alteraciones metabólicas y riesgo cardiovascular en pacientes con infecciones por el virus de la inmunodeficiencia humana]]></article-title>
<source><![CDATA[Enferm Infecc Microbiol Clin]]></source>
<year>2015</year>
<volume>33</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<collab>Centro Nacional de Información de Ciencias Médicas</collab>
<article-title xml:lang=""><![CDATA[VIH/SIDA. Estadísticas mundiales]]></article-title>
<source><![CDATA[Factográfico salud]]></source>
<year>2019</year>
<volume>5</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Veliz Castro]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Murillo Suárez]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Vargas López]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<source><![CDATA[Tiempo de adherencia a terapia antirretroviral y su asociación con parámetros bioquímicos en pacientes de la unidad de atención integral VIH sida Manta 2018]]></source>
<year>2019</year>
<publisher-loc><![CDATA[Manabí ]]></publisher-loc>
<publisher-name><![CDATA[UNESUM]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bravo Remache]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
</person-group>
<source><![CDATA[Antirretrovirales y perfil lipídico en pacientes con virus de inmunodeficiencia humana Hospital Baca Ortiz 2002-2015]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Quito ]]></publisher-loc>
<publisher-name><![CDATA[Universidad Central del Ecuador]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carvajal Alzate]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Roldan Tabares]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Herrera Almanza]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Virus de inmunodeficiencia humana: hallazgos útiles en el diagnóstico, prevención y tratamiento]]></article-title>
<source><![CDATA[Enf Inf Microbiol]]></source>
<year>2019</year>
<volume>39</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>65-70</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lantero]]></surname>
<given-names><![CDATA[MI]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Joanes]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Plan estratégico nacional para la prevención y control de las ITS, el VIH y las hepatitis 2019-2023]]></source>
<year>2019</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[Ministerio de Salud Pública]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sánchez Álvarez]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Peral Sánchez]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Cruz]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estimación del riesgo cardiovascular en pacientes con VIH]]></article-title>
<source><![CDATA[Medicentro Electrónica]]></source>
<year>2018</year>
<volume>22</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>335-42</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[González Cordón]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Enfermedad cardiovascular en la infección por el virus de la inmunodeficiencia humana. Factores implicados, tratamiento antirretroviral y utilidad de marcadores de ateromatosis subclínica]]></source>
<year>2020</year>
<publisher-loc><![CDATA[Barcelona ]]></publisher-loc>
<publisher-name><![CDATA[Universidad de Barcelona]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Del Amo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Brañas]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Serrano]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[VIH en España 2017: Políticas para una nueva gestión de la cronicidad, más allá del control virológico]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Fundación Gaspar Casal]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brennan]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
<name>
<surname><![CDATA[Jamieson]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Crowther]]></surname>
<given-names><![CDATA[NJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence, incidence, predictors, treatment, and control of hypertension among HIV-positive adults on antiretroviral treatment in public sector treatment programs in South Africa]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>201</year>
<volume>13</volume>
<numero>10</numero>
<issue>10</issue>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Africano Díaz]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez Cely]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
<name>
<surname><![CDATA[Camacho Solano]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rol actual de los inhibidores de proteasa en el manejo del paciente VIH]]></article-title>
<source><![CDATA[Infecto Médica]]></source>
<year>2019</year>
<volume>5</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[ASV]]></given-names>
</name>
<name>
<surname><![CDATA[Stelzle]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[KK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Global Burden of Atherosclerotic Cardiovascular Disease in People Living With HIV]]></article-title>
<source><![CDATA[Systematic Review and Meta-Analysis. Circulation]]></source>
<year>2018</year>
<volume>138</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1100-12</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dorjee]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Choden]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Baxi]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk of cardiovascular disease associated with exposure to abacavir among individuals with HIV: A systemstic review and meta-analyses of results from 17 epidemiologic studies]]></article-title>
<source><![CDATA[Int J Antimicrob Agents]]></source>
<year>2018</year>
<volume>52</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>541-53</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodríguez Alfaro]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gross Fernández]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Casas Gross]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Farmacovigilancia en pacientes con el virus de inmunodeficiencia humana/sida en un hospital de Zimbabwe]]></article-title>
<source><![CDATA[Medisan]]></source>
<year>2012</year>
<volume>16</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>326-32</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gueler]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Moser]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Calmy]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Life expectancy in HIV-positive persons in Switzerland: matched comparison with general population]]></article-title>
<source><![CDATA[AIDS]]></source>
<year>2017</year>
<volume>31</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>427-36</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Borges]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
<name>
<surname><![CDATA[Neuhaus]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sharma]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Effect of Interrupted/Deferred Antiretroviral Therapy on Disease Risk: A SMART and START Combined Analysis]]></article-title>
<source><![CDATA[J Infect Dis]]></source>
<year>2018</year>
<volume>219</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>254-63</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sokalski]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Chu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Mai]]></surname>
<given-names><![CDATA[AY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Endocrine abnormalities in HIV-infected women are associated with peak viral load-the children and women: antiretrovirals and markers of aging (CARMA) cohort]]></article-title>
<source><![CDATA[Clin Endocrinol (Oxf)]]></source>
<year>2016</year>
<volume>84</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>452-62</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Feinstein]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Nance]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Delaney]]></surname>
<given-names><![CDATA[JAC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mortality following myocardial infarction among HIV-infected persons: the Center for AIDS Research Network Of Integrated Clinical Systems (CNICS)]]></article-title>
<source><![CDATA[BMC Med]]></source>
<year>2019</year>
<volume>17</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Anikpo]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Agovi]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Cvitanovich]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The data-collection on adverse effects of anti-HIV drugs (D:A:D) model for predicting cardiovascular events: External validation in a diverse cohort of people living with HIV]]></article-title>
<source><![CDATA[HIV Med]]></source>
<year>2021</year>
<volume>22</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>936-43</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tsimikas]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Gordts]]></surname>
<given-names><![CDATA[PLSM]]></given-names>
</name>
<name>
<surname><![CDATA[Nora]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Statin therapy increases lipoprotein(a) levels]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2020</year>
<volume>41</volume>
<numero>24</numero>
<issue>24</issue>
<page-range>2275-84</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dávila Ascarra]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
</person-group>
<source><![CDATA[Alteraciones en el perfil lipídico en pacientes adultos. Alteraciones en el perfil lipídico en pacientes adultos con diagnóstico de infección de infección por VIH en el centro Naval entre 2013-2018]]></source>
<year>2019</year>
<publisher-loc><![CDATA[Lima ]]></publisher-loc>
<publisher-name><![CDATA[Universidad Científica del Sur]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morales Collado]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
</person-group>
<source><![CDATA[Alteraciones metabólicas de los pacientes con VIH atendidos en la clínica de atención integral Hospital Escuela Antonio Lenin Fonseca de Noviembre 2016-Enero 2017]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Managua ]]></publisher-loc>
<publisher-name><![CDATA[Universidad Nacional Autónoma de Nicaragua]]></publisher-name>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
